Showing results (21-30 of 566) with videos related to
Sort By:
Pageof 57
Bone Marrow Transplantation|August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodiesH Tesch, A Engert, O Manzke, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
The emerging role of immunotoxins in leukemia and lymphomaU Winkler, S Barth, R Schnell, et al.Medizinische Klinik (Munich, Germany : 1983)|September 25, 1999
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology]A Engert, A Josting, M Reiser, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Immunotoxins: is there a clinical value?C Gottstein, U Winkler, H Bohlen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
Current clinical trials for the treatment of adult Hodgkin's disease: common strategies and perspectivesJ Wolf, H Tesch, R Parsa-Parsi, et al.International Journal of Cancer|September 30, 1991
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in miceA Engert, G Martin, P Amlot, et al.Blood|August 15, 2000
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study GroupA Josting, U Rueffer, J Franklin, et al.Cytokine|December 1, 2000
Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSFK Hübel, G Mansmann, H Schäfer, et al.Blood|September 25, 1999
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)U Winkler, M Jensen, O Manzke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?A Josting, M Reiser, U Rueffer, et al.Pageof 57